.
CCCC financial statements
* Numbers in millions
Year |
2020 | 2021 | TTM |
|---|---|---|---|
Capitalization * |
1 473 | 1 083 | 1 133 |
EV * |
1 302 | 1 051 | 1 051 |
Stock price $ |
36.12 | 22.33 | 23.37 |
Number of shares * |
41 | 48 | 48 |
EPS |
-1,63 | -1,73 | -1,73 |
Revenue * |
33 | 46 | 46 |
Net income * |
-66 | -84 | -84 |
Operating profit * |
-60 | -82 | -82 |
Total liabilities * |
119 | 117 | 117 |
Net debt * |
-171 | -32 | -32 |
Total assets * |
400 | 507 | 507 |
Equity * |
281 | 390 | 390 |
Cash and investments * |
372 | 309 | 309 |
Over the past 10 years, the maximum capitalization of C4 Therapeutics, Inc. is 1 473, the minimum is 1 083. Maximum net income 0, Minimum net income -84. The maximum price of CCCC shares is 36.12, the minimum price is 22.33.
.
CCCC valuation
Year |
2020 | 2021 | TTM |
|---|---|---|---|
P/E |
-22,20 | -12,91 | -13,51 |
P/B |
5,24 | 2,78 | 2,91 |
P/S |
44,36 | 23,65 | 24,75 |
E/P |
-5% | -8% | -7% |
P/FCF |
-21,69 | -12,27 | -12,84 |
.
CCCC profitability
Year |
2020 | 2021 | TTM |
|---|---|---|---|
ROE |
-24% | -22% | |
ROA |
-17% | -17% | |
ROIC |
-17% | -18% |